Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

ANNÉE

2018

AUTEURS

Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS

CONGRÈS/REVUE

BMC Cancer

ÉTUDE

Localisation

LIEN PUBLICATIONS ASSOCIÉES